Article
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Journal of clinical pathology - 1 Nov 2011
Won Young-Woong, Han Ji-Youn, Lee Geon Kook, Park Seog-Yun, Lim Kun Young, Yoon Kyong-Ah, Yun Tak, Kim Heung Tae, Lee Jin Soo
Abstract excerpt
AIMS: Deletion of exon 19 of the epidermal growth factor receptor (EGFR) and mutation of exon 21 are the most common EGFR mutations and predict higher response to EGFR tyrosine kinase inhibitors (TKI). Accumulating data show clinical differences in both response and survival between these two EGFR mutations. This study investigated the clinical impact of EGFR exon 19 deletion and L858R mutation by retrospectively...
Topics
- Adult
- Aged
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Disease-Free Survival
- ErbB Receptors
- Erlotinib Hydrochloride
- Exons
- Female
- Gefitinib
- Genotype
- Humans
- Lung Neoplasms